With the spirit of non-stop exploration, Creative Biolabs has generated an all-round platform to provide TCR-like antibody services. Now, to keep pace with the world-leading immunotherapy, we are proud to introduce our innovated TCR-like CAR construction and evaluation service to our worldwide customers.
1. Background of TCR-Like CAR
It is proved to be very efficient using effector T cells which are equipped with engineered antigen receptors targeting specific cancer targets. The chimeric antigen receptors (CARs) have emerged as a useful tool to redirect T cells. However, despite very potent, CAR is limited to recognize membrane proteins which only comprise around 1% of the total proteins. There are plenty of attractive tumor antigens arising from intracellular proteins. TCR-like antibodies, which allow for specific targeting of intracellular proteins via MHC/peptide complexes, appear as an unexploited opportunity for antibody therapies. Therefore, introduction of an antigen-binding fragment from TCR-like antibody to CAR, termed TCR-like CAR, will breakthrough the antigen limitation of CAR and combines the benefits of both. This TCR-like CAR opens therapeutic avenues not only conserving the specificity and the functionality of the original TCR-like antibody, but also performing T cell signaling for cellular functions.
Fig 1 Structure of a classical TCR complex versus a tumor antigen specific CAR. (Gao J, et.al. 2012)
2. Construction and Evaluation
Creative Biolabs provides TCR-like CAR retroviral and lentiviral vector construction and functional evaluation services. Aided by rich experience on our CAR platform, we are able to construct the 1 to 4 generation of TCR-like CARs. Various intracellular signaling domains from different costimulatory protein receptors (e.g., CD28, 41BB, ICOS) can be incorporated to enhance the downstream signaling upon requisite. Both retrovirus and lentivirus can be easily used in T cell transfection, thus T cells can be modified with the designed CARs. Plenty of in vitro and in vivo assays are used to evaluate the TCR-like CARs prior to further application. To obtain high-quality TCR-like CAR-T cells, transgene expression measurement, specificity and affinity control, cytokine release test, cytotoxicity and proliferation analysis of modified cells, efficacy test, etc are all available to perform on our well-established platform. Of note, we also have more than 200 cell line xenograft mice or rats models to help you generate a most promising therapeutic TCR-like CAR. In addition, given to close collaborations with global hospitals, it is relatively easy to access to patient primary cancer cells, thus we are capable of creating cell-derived xenograft (CDX) models.
3. Highlight Features of Our Service
➢ One-stop pipeline
We provide one-stop package to generate a TCR-like CAR from initially antigen specific TCR-like antibody discovery to CAR vector construction, followed by versatile in vitro and in vivo evaluation assays.
➢ All-round platforms
We offer both superior TCR-like antibody discovery and CAR-T cell therapy development platforms. Now TCR-like CAR is an innovated combination of these two platforms.
➢ Tightly quality control
Robust quality control assays are performed prior to each next step.
➢ Skillful scientific team
We are good at timely troubleshooting to each customized project.
Creative Biolabs has always been devoted to giving a hand in the biological drug discovery of tomorrow. Empowered by our state-of-the-art technologies and platforms, we are more than confident to support each specific project in your immunotherapy for academic or commercial purpose. Please feel free to contact us and we will not let you down.
Gao J J, Bernatchez C, Sharma P, et al. (2012). Advances in the development of cancer immunotherapies. Trends in Immunology. 34(2), 90-98.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE